Gluco and galacto-oligosaccharides in food: Update on health effects and relevance in healthy nutrition

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 16, Issue 6, 2013, Pages 675-678

  Rastall, Robert A ^a  

^a UNIVERSITY OF READING   (United Kingdom)

Author keywords

galacto oligosaccharides; gluco oligosaccharides; prebiotics

Indexed keywords

GALACTOSE OLIGOSACCHARIDE; GLUCOSE OLIGOSACCHARIDE; OLIGOSACCHARIDE; PREBIOTIC AGENT; UNCLASSIFIED DRUG;

CALCIUM ABSORPTION; DIETARY INTAKE; FOOD; FOOD INTAKE; HUMAN; IMMUNITY; METABOLIC SYNDROME X; NUTRITION; REVIEW;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; MICROBIOTA; NUTRITIONAL STATUS; OLIGOSACCHARIDES; PREBIOTICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84886418573     PISSN: 13631950     EISSN: 14736519     Source Type: Journal    
DOI: 10.1097/MCO.0b013e328365b5fd     Document Type: Review

References (25)

1. Gibson G, Scott K, Rastall RA, et al. Dietary prebiotics: current status and new definition. IFIS Functional Foods Bulletin 2010; 7:1-19.
2. Rastall RA. Functional oligosaccharides: application and manufacture. Ann Rev Food Sci Technol 2010; 1:305-339.
3. Barile D, Rastall RA. Human milk and related oligosaccharides as prebiotics. Curr Opin Biotechnol 2013; 24:214-219.
4. Wooley JC, Godzik A, Friedberg I. A primer on metagenomics. PLoS Comput Biol 2010; 6:1-13.
5. Thomas T, Gilbert J, Meyer F. Metagenomics: a guide from sampling to data analysis. Microb Inform Exp 2012; 2:3-12.
6. Davis LMG, Mart?nez I, Walter J, et al. Barcoded pyrosequencing reveals that consumption of galactooligosaccharides results in a highly specific bifidogenic response in humans. PLoS One 2011; 6:1-10.
7. Clemente A, Rubio LA, Sanz Y, et al. Multifunctional galacto- oligosaccharides derived from lactulose with immunomodulatory and prebiotic activities. Spanish patent 2011; P201130784.
8. Marin-Manzano M, Abecia L, Hernandez-Hernandez O, et al. Galacto-oligosaccharides derived from lactulose exert a selective stimulation on the growth of Bifidobacterium animalis in large intestine of growing rats. J Agric Food Chem 2013; 61:7560-7567.
9. Cardelle-Cobas A, Agustín Olano A, Corzo N, et al. In vitro fermentation of lactulose-derived oligosaccharides by mixed fecal microbiota. J Agric Food Chem 2012; 60:2024-2032.
10. Hernandez-Hernandez O, Marin-Manzano M, Rubio LA, et al. Monomer and linkage type of galacto-oligosaccharides affect their resistance to ileal digestion and prebiotic properties in rats. J Nutr 2012; 142:1232-1239.
11. Delzenne NM, Neyrinck AM, Cani PD. Gut microbiota and metabolic disorders: how prebiotic can work? Br J Nutr 2013; 109:S81-S85.
12. Overduin J, Schoterman MHC, Calame W, et al. Dietary galacto- oligosaccharides and calcium: effects on energy intake, fat-pad weight and satietyrelated, gastrointestinal hormones in rats. Br J Nutr 2013; 109:1338-1348.
13. Cani PD, Delzenne NM. The gut microbiome as therapeutic target. Pharmacol Ther 2011; 130:202-212.
14. Whisner CM, Martin BR, Schoterman MHC, et al. Galacto-oligosaccharides increase calcium absorption and gut bifidobacteria in young girls: a doubleblind cross-over trial. Br J Nutr 2013; 110:1292-1303.
15. Searle LEJ, Jones G, Tzortzis G, et al. Low molecular weight fractions of BiMuno exert immunostimulatory properties in murine macrophages. J Funct Foods 2012; 4:941-953.
16. Vulevic J, Juric A, Tzortzis G, et al. A mixture of trans- galactooligosaccharides reduces markers of metabolic syndrome and modulates the fecal microbiota and immune function of overweight adults. J Nutr 2013; 143:324-331.
17. Walton G, van deHeuvel E, KostersMH, et al. A randomised crossover study investigating the effects of galacto-oligosaccharides on the faecal microbiota in men and women over 50 years of age. Br J Nutr 2012; 107:1466-1475.
18. Staudacher HM, Lomer MCE, Anderson JL, et al. Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome. J Nutr 2012; 142:1510-1518.
19. Obendorf RL, Górecki RJ. Soluble carbohydrates in legume seeds. Seed Science Research 2012; 22:219-242.
20. Silk DBA, Davis A, Vulevic J, et al. Clinical trial: the effects of a transgalactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. Aliment Pharmacol Ther 2009; 29:508-518.
21. Vigsnaes LK, Nakai H, Hemmingsen L, et al. In vitro growth of four individual human gut bacteria on oligosaccharides produced by chemoenzymatic synthesis. Food Funct 2013; 4:784-793.
22. Brison Y, Fabre E, Moulis C, et al. Synthesis of dextrans with controlled amounts of -1,2 linkages using the transglucosidase GBD-CD2. Appl Microbiol Biotechnol 2010; 86:545-554.
23. Sarbini SR, Kolida S, Naeye T, et al. In vitro fermentation of linear and alpha- 1,2-branched dextrans by the human fecal microbiota. Appl Environ Microbiol 2011; 77:5307-5315.
24. Sarbini SR, Kolida S, Gibson GR, et al. In vitro fermentation of commercial agluco- oligosaccharide by faecal microbiota from lean and obese human subjects. Br J Nutr 2013; 109:1980-1989.
25. Sokol H, Pigneur B, Watterlot L, et al. Faecalibacterium prausnitzii is an antiinflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. PNAS 2008; 105:16731-16736.